Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials

被引：0

作者：

Metts, Jonathan L. ^{[1
,2
]}

Aye, Jamie M. ^{[3
]}

Crane, Jacquelyn N. ^{[4
,5
]}

Oberoi, Sapna ^{[6
,7
]}

Balis, Frank M. ^{[4
]}

Bhatia, Smita ^{[8
]}

Bona, Kira ^{[9
,10
]}

Carleton, Bruce ^{[11
]}

Dasgupta, Roshni ^{[12
]}

Dela Cruz, Filemon S. ^{[13
]}

Greenzang, Katie A. ^{[9
,10
]}

Kaufman, Jonathan L. ^{[14
,15
]}

Linardic, Corinne M. ^{[16
,17
]}

Parsons, Susan K. ^{[18
,19
]}

Robertson-Tessi, Mark ^{[20
]}

Rudzinski, Erin R. ^{[21
,22
]}

Soragni, Alice ^{[23
,24
]}

Stewart, Elizabeth ^{[25
]}

Weigel, Brenda J. ^{[26
]}

Wolden, Suzanne L. ^{[27
]}

Weiss, Aaron R. ^{[28
]}

Venkatramani, Rajkumar ^{[29
]}

Heske, Christine M. ^{[30
]}

机构：

[1] Moffitt Comprehens Canc Ctr, Sarcoma Dept, Tampa, FL USA

[2] Johns Hopkins All Childrens Hosp, Canc & Blood Disorders Inst, St Petersburg, FL USA

[3] Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol & Oncol, Birmingham, AL USA

[4] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA USA

[5] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Dept Pediat, Philadelphia, PA USA

[6] Canc Care Manitoba, Dept Pediat Hematol & Oncol, Winnipeg, MB, Canada

[7] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB, Canada

[8] Univ Alabama Birmingham, Inst Canc Outcomes & Survivorship, Heersink Sch Med, Birmingham, AL USA

[9] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA

[10] Dana Farber Canc Inst, Div Populat Sci, Boston, MA USA

[11] Univ British Columbia, Fac Med, Dept Pediat, Div Translat Therapeut, Vancouver, BC, Canada

[12] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Pediat Gen & Thorac Surg, Cincinnati, OH 45221 USA

[13] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY USA

[14] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA USA

[15] Patient Advocacy Comm, Childrens Oncol Grp, Monrovia, CA USA

[16] Duke Univ, Sch Med, Dept Pediat, Durham, NC USA

[17] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC USA

[18] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA

[19] Tufts Med Ctr, Div Hematol Oncol, Boston, MA USA

[20] H Lee Moffitt Canc Ctr & Res Inst, Integrated Math Oncol Dept, Tampa, FL USA

[21] Seattle Childrens Hosp, Dept Lab Med & Pathol, Seattle, WA USA

[22] Univ Washington, Med Ctr, Seattle, WA USA

[23] Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA USA

[24] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[25] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN USA

[26] Univ Minnesota, Div Pediat Hematol & Oncol, Minneapolis, MN USA

[27] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA

[28] Maine Med Ctr, Dept Pediat, Portland, ME USA

[29] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX USA

[30] NCI, Pediat Oncol Branch, Ctr Canc Res, Bethesda, MD USA

来源：

CANCER | 2024年 / 130卷 / 22期

关键词：

clinical trials; novel agents; pediatric; quality of life; rhabdomyosarcoma; PATIENT-REPORTED OUTCOMES; TISSUE SARCOMA COMMITTEE; RISK RHABDOMYOSARCOMA; PEDIATRIC-PATIENTS; 1ST RELAPSE; RADIOTHERAPY; VINCRISTINE; THERAPY; CLASSIFICATION; IMPLEMENTATION;

D O I：

10.1002/cncr.35457

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical trials conducted by the Intergroup Rhabdomyosarcoma (RMS) Study Group and the Children's Oncology Group have been pivotal to establishing current standards for diagnosis and therapy for RMS. Recent advancements in understanding the biology and clinical behavior of RMS have led to more nuanced approaches to diagnosis, risk stratification, and treatment. The complexities introduced by these advancements, coupled with the rarity of RMS, pose challenges to conducting large-scale phase 3 clinical trials to evaluate new treatment strategies for RMS. Given these challenges, systematic planning of future clinical trials in RMS is paramount to address pertinent questions regarding the therapeutic efficacy of drugs, biomarkers of response, treatment-related toxicity, and patient quality of life. Herein, the authors outline the proposed strategic approach of the Children's Oncology Group Soft Tissue Sarcoma Committee to the next generation of RMS clinical trials, focusing on five themes: improved novel agent identification and preclinical to clinical translation, more efficient trial development and implementation, expanded opportunities for knowledge generation during trials, therapeutic toxicity reduction and quality of life, and patient engagement.

引用

页码：3785 / 3796

页数：12

共 50 条

[21] Outcomes for patients with perineal and perianal rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
Dasgupta, Roshni
Xue, Wei
Dixon, Andrea Hayes
Wolden, Suzanne
Yock, Torunn I.
Venkatramani, Rajkumar
Rodeberg, David A.
PEDIATRIC BLOOD & CANCER, 2024,
[22] Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies
Schloemer, Nathan J.
Xue, Wei
Qumseya, Amira
Luo, Leo Y.
Hiniker, Susan M.
Lautz, Timothy B.
Rhee, Daniel S.
Arnold, Michael A.
Venkatramani, Rajkumar
PEDIATRIC BLOOD & CANCER, 2024, 71 (10)
[23] Children's Oncology Group's 2013 blueprint for research: Radiation oncology
Merchant, Thomas E.
Hodgson, David
Laack, Nadia N. I.
Wolden, Suzanne
Indelicato, Danny J.
Kalapurakal, John A.
PEDIATRIC BLOOD & CANCER, 2013, 60 (06) : 1037 - 1043
[24] Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group
Crane, Jacquelyn N.
Xue, Wei
Qumseya, Amira
Gao, Zhengya
Arndt, Carola A. S.
Donaldson, Sarah S.
Harrison, Douglas J.
Hawkins, Douglas S.
Linardic, Corinne M.
Mascarenhas, Leo
Meyer, William H.
Rodeberg, David A.
Rudzinski, Erin R.
Shulkin, Barry L.
Walterhouse, David O.
Venkatramani, Rajkumar
Weiss, Aaron R.
PEDIATRIC BLOOD & CANCER, 2022, 69 (06)
[25] Sclerosing rhabdomyosarcomas in children and adolescents: A clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group
Chiles, MC
Parham, DM
Qualman, SJ
Teot, LA
Bridge, JA
Ullrich, F
Barr, FG
Meyer, WH
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 2004, 7 (06) : 583 - 594
[26] REGIONAL NODAL INVOLVEMENT AND PATTERNS OF SPREAD ALONG IN-TRANSIT PATHWAYS IN CHILDREN WITH RHABDOMYOSARCOMA OF THE EXTREMITY: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
La, Trang H.
Wolden, Suzanne L.
Rodeberg, David A.
Hawkins, Douglas S.
Brown, Kenneth L.
Anderson, James R.
Donaldson, Sarah S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (04): : 1151 - 1157
[27] Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group
Casey, Dana L.
Chi, Yueh-Yun
Donaldson, Sarah S.
Hawkins, Douglas S.
Tian, Jing
Arndt, Carole A.
Rodeberg, David A.
Routh, Jonathan C.
Lautz, Timothy B.
Gupta, Abha A.
Yock, Torunn, I
Wolden, Suzanne L.
CANCER, 2019, 125 (18) : 3242 - 3248
[28] Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children's Oncology Group
Lupo, Philip J.
Danysh, Heather E.
Skapek, Stephen X.
Hawkins, Douglas S.
Spector, Logan G.
Zhou, Renke
Okcu, M. Fatih
Papworth, Karin
Erhardt, Erik B.
Grufferman, Seymour
CANCER CAUSES & CONTROL, 2014, 25 (07) : 905 - 913
[29] Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group
Arnold, Michael A.
Anderson, James R.
Gastier-Foster, Julie M.
Barr, Frederic G.
Skapek, Stephen X.
Hawkins, Douglas S.
Raney, R. Beverly, Jr.
Parham, David M.
Teot, Lisa A.
Rudzinski, Erin R.
Walterhouse, David O.
PEDIATRIC BLOOD & CANCER, 2016, 63 (04) : 634 - 639
[30] Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children’s Oncology Group
Philip J. Lupo
Heather E. Danysh
Stephen X. Skapek
Douglas S. Hawkins
Logan G. Spector
Renke Zhou
M. Fatih Okcu
Karin Papworth
Erik B. Erhardt
Seymour Grufferman
Cancer Causes & Control, 2014, 25 : 905 - 913

← 1 2 3 4 5 →